Novo Nordisk | NVO - Cost Of Sales

Stock Price
44.74
Daily Change
-1.10 -2.40%
Monthly
9.44%
Yearly
-30.48%
Q2 Forecast
42.62

Novo Nordisk reported DKK1.95B in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Bausch Health Companies USD 979M 55M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.46B 83M Mar/2026
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Zoetis USD 672M 71M Mar/2026